Rosiglitazone has demonstrated reduced inflammatory markers and superoxide anion production with inhibition of ubiquitin-proteasome activity in atherosclerotic plaques of T2DM patients (140), while Pioglitazone systemically has demonstrated reduced adipose tissue macrophage activity resulting in decreased pro-inflammatory cytokines (IL-6, IL-1B) in neutrophils, macrophages and dendritic cells of peripheral organs (140). This evidence concerns the gene IL6 and type 2 diabetes mellitus.